The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for Merck‘s Winrevair (sotatercept-csrk) that more specifically details how the pulmonary arterial hypertension (PAH) therapy reduces the risk of serious complications. Winrevair was approved by the FDA last year to improve…
News
From 1990 to 2021, cases of pulmonary arterial hypertension (PAH) increased worldwide among older adults, mainly due to growing aging populations. Elderly women were found to face the highest risk of death, according to data from the Global Burden of Disease Study. “Our findings provided a novel global perspective…
An eight-week exercise program using kettlebells — a weight tool consisting of a heavy cast-iron ball and handle — led to gains in physical performance, breathing efficiency, and muscle strength in people with pulmonary arterial hypertension (PAH), according to a new study from Turkey. Kettlebell training also improved quality…
Treatment with anticoagulants, also known as blood thinners, does not extend survival in people with pulmonary arterial hypertension (PAH), according to a large French study. These findings were supported by an additional pooled analysis of published studies involving more than 2,000 PAH patients, researchers found. “From the most rigorous…
Global death rates and levels of disability among newborns with pulmonary arterial hypertension (PAH) have declined since 1990, while the incidence of new cases has remained stable, according to a 30-year analysis. Still, mortality and disability rates are disproportionately higher in countries with low economic status, “underscoring the critical…
Researchers used computer-based modeling to develop a measure, called pulmonary vascular compromise (PVC), which estimates the reduced function of the pulmonary blood vessels in children with pulmonary arterial hypertension (PAH), according to a study. Supported by clinical data, a higher PVC, meaning a loss of the pulmonary vasculature, was…
Long-term treatment with Tyvaso DPI safely and effectively leads to increases in exercise capacity in adults with pulmonary arterial hypertension (PAH). Tyvaso DPI is a dry powder, inhaled form of treprostinil. Patient satisfaction was also improved with Tyvaso DPI compared with Tyvaso, which is a nebulized, inhaled formulation…
A new sequential strategy successfully treats people with severe chronic thromboembolic pulmonary hypertension (CTEPH), significantly reducing high blood pressure and improving heart function, a study finds. The three-step regimen — medication, balloon pulmonary angioplasty (BPA), and pulmonary endarterectomy (PEA) surgery — is designed for people facing unacceptably high surgical…
A new experimental therapy for pulmonary arterial hypertension (PAH), called ALG-801, has shown superior efficacy over current standard-of-care treatments in early laboratory studies, according to its developer, Alivegen. In animal testing, the medication reduced signs of the disease by targeting a molecular pathway involved in the abnormal growth…
Worldwide, pulmonary arterial hypertension (PAH) affects more than 2 of every 100,000 females ages 15 to 49 — women and girls of childbearing age — according to a new analysis of data spanning some three decades. The researchers noted that the rates of PAH vary substantially in different parts…
The PAH Initiative is hosting video events in November to discuss the importance of shared decision making between doctors and patients to help manage pulmonary arterial hypertension (PAH). The hour-long broadcasts, which are intended for adults with PAH and their caregivers, will take place at 8 p.m. EST…
Winrevair (sotatercept-csrk), when added to standard of care, reduced clinical worsening events by 76% in adults recently diagnosed with pulmonary arterial hypertension (PAH). That’s according to now-published data from the Phase 3 HYPERION (NCT04811092) clinical trial, which evaluated …
